CYP2C19 and type 2 diabetes mellitus: These studies reported that patients with T2DM comorbidity have reduced anti-platelet efficacy of clopidogrel compared to controls, suggesting some alterations in the activation of the prodrug by CYP2C19 [139,144,145].